2024
Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.Peer-Reviewed Original ResearchAcute myeloid leukemiaAnti-PD-L1 antibody durvalumabOverall response rateMyelodysplastic syndromeComplete responseBM aspiratesMyeloid leukemiaInternational Working GroupBone marrowMyelodysplastic syndromes treated with azacitidineAcute myeloid leukemia ptsWild-type acute myeloid leukemiaSecondary acute myeloid leukemiaResponse criteriaAnti-PD-L1Immune checkpoint inhibitorsTreated with azacitidineOutcomes of patientsAny-cause deathGeneration of neoantigensVariant allele frequencySusceptible to treatmentMarrow CRAdverse cytogeneticsCheckpoint inhibitors
2023
Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms
Bale S, Kim C, How J, Wazir M, Weeks L, Stahl M, Luskin M, DeAngelo D, Lindsley C, Kim A, Mullally A, Marneth A. Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms. Blood 2023, 142: 1788. DOI: 10.1182/blood-2023-178657.Peer-Reviewed Original ResearchVariant allele frequencySRSF2 mutationsCALR mutationsMyeloproliferative neoplasmsU2AF1 mutationsPathogenic mutationsSplicing factor mutationsCo-mutationsGene mutationsMPN phenotypic driver mutationsPolymerase chain reactionDriver mutationsMyeloproliferative neoplasm driver mutationsSplicing factor genes mutationsCD34-positive bone marrow cellsPositive bone marrow cellsPhenotypic driver mutationsSpliceosome gene mutationsNegative myeloproliferative neoplasmsComprehensive molecular profilingMyeloproliferative neoplasm patientsHematopoietic growth factorsBone marrow cellsSplicing factor U2AF1Pathogenic mutation(s
2021
Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival
Badar T, Litzow M, Shallis R, Bewersdorf J, Saliba A, De Camargo Correia G, Stahl M, Goldberg A, Atallah E, Foran J. Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood 2021, 138: 797. DOI: 10.1182/blood-2021-147639.Peer-Reviewed Original ResearchCR/CRiProportion of patientsStem cell transplantationComplex cytogeneticsVariant allele frequencyCPX-351Overall survivalAML patientsNovel therapiesTP53 mutationsCell transplantationUnivariate analysisAllogeneic hematopoietic stem cell transplantationMedian progression-free survivalAllogeneic stem cell transplantationHematopoietic stem cell transplantationAdvisory CommitteeAML induction therapyExtra-medullary diseaseHigh-risk AMLInduction/consolidationVenetoclax combination therapyVenetoclax-based regimensMedian overall survivalMulticenter observational study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply